HK1142128A1 - Methods of prognosis - Google Patents

Methods of prognosis

Info

Publication number
HK1142128A1
HK1142128A1 HK10108448.9A HK10108448A HK1142128A1 HK 1142128 A1 HK1142128 A1 HK 1142128A1 HK 10108448 A HK10108448 A HK 10108448A HK 1142128 A1 HK1142128 A1 HK 1142128A1
Authority
HK
Hong Kong
Prior art keywords
prognosis
methods
Prior art date
Application number
HK10108448.9A
Other languages
English (en)
Chinese (zh)
Inventor
Samuel Norbert Breit
David Alexander Brown
Henrik Grnberg
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007905761A external-priority patent/AU2007905761A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of HK1142128A1 publication Critical patent/HK1142128A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK10108448.9A 2007-10-22 2010-09-06 Methods of prognosis HK1142128A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007905761A AU2007905761A0 (en) 2007-10-22 Methods of prognosis
PCT/AU2008/001554 WO2009052557A1 (fr) 2007-10-22 2008-10-22 Procédés de pronostic

Publications (1)

Publication Number Publication Date
HK1142128A1 true HK1142128A1 (en) 2010-11-26

Family

ID=40578957

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108448.9A HK1142128A1 (en) 2007-10-22 2010-09-06 Methods of prognosis

Country Status (8)

Country Link
US (4) US20110039284A1 (fr)
EP (1) EP2208072B1 (fr)
JP (2) JP5272011B2 (fr)
CN (1) CN101861522B (fr)
CA (1) CA2701945A1 (fr)
ES (1) ES2543985T3 (fr)
HK (1) HK1142128A1 (fr)
WO (1) WO2009052557A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20120107420A1 (en) * 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
WO2011050407A1 (fr) * 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Procédés de diagnostic et de pronostic de polypes du côlon
EP2573566A1 (fr) * 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 dans le pronostic du cancer de la prostate
EP2830646B1 (fr) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
KR20170065026A (ko) 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US11686731B2 (en) * 2015-01-05 2023-06-27 Ian Mills Prostate cancer markers and uses thereof
WO2016160545A1 (fr) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Standards d'antigènes prostatiques et utilisations
US11604194B2 (en) 2016-02-29 2023-03-14 Public University Corporation Yokohama City University Method for detecting castration-resistant prostate cancer and detection reagent
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994003599A1 (fr) * 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6521227B1 (en) * 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) * 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1998014582A1 (fr) * 1996-09-30 1998-04-09 Human Genome Sciences, Inc. Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6465181B2 (en) * 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ES2346918T3 (es) * 2000-04-20 2010-10-21 St Vincent's Hospital Sydney Limited Ensayo para diagnostico que involucra a la citoquina-1 (mic-1) inhibidora de macrofagos.
CA2432991A1 (fr) * 2001-01-23 2002-08-01 Irm, Llc Genes surexprimes dans des maladies de la prostate servant de cibles diagnostiques et therapeutiques
US20030113744A1 (en) * 2001-05-11 2003-06-19 O' Toole Margot M. Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof
WO2003016484A2 (fr) * 2001-08-17 2003-02-27 Affymetrix, Inc. Genes du cancer de la prostate de score de gleason 4/5
AU2003228811A1 (en) * 2002-05-01 2003-11-17 Irm Llc Methods for discovering tumor biomarkers and diagnosing tumors
US7919084B2 (en) * 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2390820A1 (fr) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methodes de diagnostic, de pronostic et de traitement de maladies cardiovasculaires
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer

Also Published As

Publication number Publication date
US20200003780A1 (en) 2020-01-02
WO2009052557A1 (fr) 2009-04-30
CN101861522A (zh) 2010-10-13
CN101861522B (zh) 2014-05-14
EP2208072A4 (fr) 2011-01-26
JP5734342B2 (ja) 2015-06-17
US20230059466A1 (en) 2023-02-23
JP2011501136A (ja) 2011-01-06
JP5272011B2 (ja) 2013-08-28
JP2013174614A (ja) 2013-09-05
EP2208072A1 (fr) 2010-07-21
US20160018401A1 (en) 2016-01-21
ES2543985T3 (es) 2015-08-26
EP2208072B1 (fr) 2015-07-01
US20110039284A1 (en) 2011-02-17
CA2701945A1 (fr) 2009-04-30

Similar Documents

Publication Publication Date Title
HK1142128A1 (en) Methods of prognosis
GB0706709D0 (en) Methods
ZA201001878B (en) Improved detection of mage-a-expression
GB0711697D0 (en) Method of manufacture
HK1132673A1 (en) Novel methods
AP2008004406A0 (en) Methods of managing timberland
EP2234642A4 (fr) Méthode propre à accroître un effet immunologique
IL201054A0 (en) New methods
GB0705854D0 (en) Methods of construction
GB0718160D0 (en) Methods
AP2784A (en) Methods of managing timberland
EP2342355A4 (fr) Procédés d'utilisation de biomarqueurs
GB0701599D0 (en) Method of detection
ZA200900636B (en) Method of prognosis
EP2161998A4 (fr) Nouveaux composés chimiques et nouveaux procédés d'utilisation de ceux-ci
EP2205524A4 (fr) Procédés de fabrication de bore en grappe
GB0715502D0 (en) Methods
GB0714842D0 (en) Methods
GB0707735D0 (en) Methods
TWI348657B (en) Determination method of edge direction
GB0711140D0 (en) New methods
GB201114396D0 (en) Location of basesation
GB0719252D0 (en) Methods
GB0713673D0 (en) Methods
AU2007905761A0 (en) Methods of prognosis

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: GR